CNSPulse
W121

A NOVEL INTERACTIVE DIGITAL LEARNING TOOL (DISCOVER TD®) FOR PSYCHIATRY RESIDENT TRAINING ON DIAGNOSIS AND TREATMENT OF DRUG-INDUCED MOVEMENT DISORDERS

Jasmine Modasi — Bijal Sheth2, M. Mercedes Rodriguez-Perez1 1Icahn School of Medicine at Mount Sinai, 2Neurocrine Biosciences

2026 ASCP Annual Meeting

Background

Misdiagnosis and underdiagnosis are key obstacles to adequate treatment of drug-induced movement disorders (DIMDs) that may lead to incorrect intervention and worsening of symptoms. Training psychiatrists to recognize and differentiate between different types of DIMDs is crucial to guiding treatment. Current gold standards for training in the assessment and management of drug-induced abnormal involuntary movements are lacking. Digital learning tools (DLT) have been shown to be more effective than traditional instructional approaches in medical school, yet DLT approaches are lacking in psychiatry residency training. This study aimed to analyze the use and effectiveness of the interactive digital tool, Discover TD, for improving knowledge about assessment and management of DIMDs in psychiatry residents.

Method

A random nationwide sample of psychiatry residents were invited to complete a preintervention quiz, a set of Discover TD educational modules (“cases”), and 2 follow-up quizzes, at 2 weeks and 3 months, respectively. Discover TD is an interactive digital learning tool developed by Neurocrine Biosciences, providing an educational experience using case-based examples of various DIMDs and interactions with virtual avatar patients. Participants are guided through a stepwise process to observe the patient, chat about signs and symptoms, and assess and treat abnormal involuntary movements. Diagnosis accuracy, treatment accuracy, and overall case performance accuracy were scored from 0-100%. Predictors of baseline knowledge and performance were explored using correlations and regression models.

Results

Seventy-six psychiatry residents registered for the study, 67 (88%) completed at least one case, and 42 (55%) completed all 9 cases within 4 weeks. Sixty (80%) reported prior training in drug-induced abnormal involuntary movements and 59 (79%) reported prior experience administering at least one abnormal involuntary movement scale. The mean pre-quiz, case accuracy, diagnosis accuracy, and treatment accuracy score were 69% (SD=16%), 63% (SD=32%), 55% (SD=33%), and 39% (SD=32%), respectively. No differences in demographics, training factors, or pre-quiz scores were found between case completers (  1 case) and noncompleters ( < 1 case). Number of cases completed predicted diagnosis (p < .0001), treatment (p < .0001), and overall case score (p < .001), controlling for prior experience, training factors, and pre-quiz score. Correlations between pre-quiz score and performance (case performance, diagnosis accuracy, and treatment accuracy) were nonsignificant.

Conclusions

The results show preliminary evidence that the assessment and treatment accuracy of DIMDs improve with the number of completed Discover TD cases. Future directions include assessing whether case performance gains transfer to improved knowledge about DIMD at 2weeks and 3-months follow-up. These results advance our knowledge about the utility of DLT in psychiatry residency training.